NYSE ARCA | ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index.
The index seeks to track the performance of the common stock ofU. S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| ALPN | Alpine Immune Sciences Inc | Healthcare | Biotechnology | 2.68% |
| LBPH | Longboard Pharmaceuticals Inc | Healthcare | Biotechnology | 2.54% |
| NVAX | Novavax Inc | Healthcare | Biotechnology | 2.12% |
| AKRO | Akero Therapeutics Inc | Healthcare | Biotechnology | 1.87% |
| GERN | Geron Corporation | Healthcare | Biotechnology | 1.84% |
| 6XC | SOLENO THERAPEUT. DL-001 | Healthcare | Biotechnology | 1.76% |
| MORF | Morphic Holding Inc | Healthcare | Biotechnology | 1.74% |
| ANAB | AnaptysBio Inc | Healthcare | Biotechnology | 1.65% |
| MRUS | Merus BV | Healthcare | Biotechnology | 1.58% |
| LQDA | Liquidia Technologies Inc | Healthcare | Biotechnology | 1.58% |
| CVAC | CureVac NV | Healthcare | Biotechnology | 1.54% |
| XERS | Xeris Pharmaceuticals Inc | Healthcare | Biotechnology | 1.44% |
| MLYS | Mineralys Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | 1.40% |
| ETNB | 89bio Inc | Healthcare | Biotechnology | 1.36% |
| ITOS | Iteos Therapeutics Inc | Healthcare | Biotechnology | 1.34% |
| PTGX | Protagonist Therapeutics Inc | Healthcare | Biotechnology | 1.33% |
| TSHA | Taysha Gene Therapies Inc | Healthcare | Biotechnology | 1.30% |
| KRYS | Krystal Biotech Inc | Healthcare | Biotechnology | 1.28% |
| NK | NantKwest Inc | Healthcare | Biotechnology | 1.23% |
| RGNX | Regenxbio Inc | Healthcare | Biotechnology | 1.22% |